WVT078 administered with and without WHG626 showed a manageable safety profile. Preliminary activity was observed in patients with r/r MM. The addition of WHG626 numerically improved response over WVT078 monotherapy. Findings from this study support further evaluation of WHG626 as a combination partner of BCMA-targeting agents for r/r MM treatment.
Final clinical data of a phase 1 dose‐escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ‐secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Fredrik Schjesvold·Marc S. Raab·Yaël C. Cohen·Enrique M. Ocio·Jordi López‐Pardo·Anna Maria Cafro·Natalie S. Callander·J. H. Kaufman·Meera Mohan·Martin Wermke·Noriko Doki·Rebecca Kan·Pedro Milanez‐Almeida·Andrew M. Stein·Gina M. Trabucco·S. Ye·Karolina Kulec·Romain Séchaud·Souvik Banerjee·Huiqin Zhong·Clinton Lai·Philipp J. Rauch·Andrew Spencer